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1. INTRODUCTION 
Interleukin-I (IL-I) is a cytokine polypeptide product 
called tnonokine with a broad range of biological ac- 
tions, including the regulation of the immune system 
[l-5]. This monokine is generated by a variety of cell 
types including monocyte-macrophage c lls, which play 
important roles in several phases of the immune 
response to both foreign (including mitogens) and some 
self antigens [6,7]. It has been reported by many 
authors that the role of the antigen in activating 
macrophages for the production of monokines and T- 
cell activation is very critical to thL host’s immune 
response [8] I
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Interleukin-I (IL-l), mainly produced by monocyte-maceophagcs, isa polypeptide cytokine with pleiotropic biological effects. IL-1 plays an impor- 
tant role in mediating immune response and inflammation. Recently a natural inhibitor to IL-I has been discovered, interleukin-1 receptor antago- 
nist (IL-lra), produced by human monocytes cultured on adherent IgG which binds to the IL-I receptors. In our study we found that the pretreat- 
ment of cells with serial dilutions of IL-lra (250 r&ml-25 pg/ml) inhibits, in a dose-dependent manner, lymphocyte DNA synthesis stimulated 
with Con A (10 @g/ml). IL-Ira did not have any effect on resting peripheral blood mononuclear cells (PBMC). Time course experiments how 
that IL-lra at 250 ng/ml has its maximum inhibitory effect on lymphocyte blastogenesis when cells are pretreated 2 h before Con A. No effect 
was found when hrIL-lra was added after Con A. Moreover, hrll-lra also inhibits the enhancing effects of exogenous hrIL-1 (400, 200, 100 and 
50 ng/ml) on lymphocytes stimulated with Con A; while when hrIL-lra was used on cells treated with only Con A, the inhibition was more pro- 
nounced. When PBMC were removed from monocytes, by adherence, the Con A-treated lymphocytes were not influenced by 2 h pretreatment 
of hrIL-lra; while a strong inhibition was found when exogenous hrIL-I was added at different concentrations. In addition, hrIL-lra also inhibits 
the enhancing effect of hrIL-2 on lymphocyte DNA synthesis. In another set of experiments PBMC were pretreated with hrIL-lra (250 &ml) 
for 2 h and then added LPs (10 n&ml) and IL-IK generation was determined using ELISA. In these experiments IL-lra completely abolished the 
generation of IL-la. These data suggest hat hrIL-1 ra exhibits a dose-response inhibition of lymphocyte blastogenesis induced by Con A, probably 
through the down-regulation of IL-1 synthesis necessary as an early signal for T-cell activation and IL-2 production. 
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Recently, two independent groups have described a 
natural inhibitor to IL-l [S-11]. This protein which 
binds to the IL-I receptor, is called IL-l receptor an- 
tagonist and has been proved to have interesting 
biological properties [ 12,131. Human recombinant 
interleukin-1 receptor antagonist (hrIL-lra) is a 
monokine secreted by macrophages with a chemical 
structure similar to hrIL-l@ but with different 
bi,ological activity. We have recently found that hrIL-14 
and IL-la have similar biological effects on natural 
killer cell activity in potentiating the stimulatory effects 
of IL-2 [14], Moreover, hrIL-lra inhibits IL-la and 
IL-l,8 stimulation of PGE2 production in human 
synovial cells [ 121. Various in vitro T lymphocyte func- 
tions are initiated or potentiated by contact with 
specific lymphokines. Resting peripheral blood T lym- 
phocytes can be activated to proliferate after interacting 
with polyclonal mitogens or antigens IL-I is the first 
signal inducing the expression of IL-2 receptors on the 
surface of a subpopulation of T cells and the binding of 
IL-1 to its receptor leads the cells to initiate DNA syn- 
thesis [ 151, 8 process mediated by the binding of IL-2 to 
I37 
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its receptor. Since there are many immunological 
changes attributed to hrIL-1, including its effects on the 
augmentation of T cell proliferation to mitogen and an- 
tigens, a property known as lymphocyte activating fac- 
tor (LAP) [16], it is pertinent to study the effects of 
hrIL-Ira on lymphocyte blastogenesis induced by a 
mitogen, concanavalin A (Con A) and its influence on 
LPS stimulated peripheral blood mononuclear cell pro- 
duction of IL-lcu. 
2. MATERIALS AND IvIETHODS 
2.1. Peripheral blood mononuclear cells (PBMC) preparation 
Cell suspensions were prepared from heparinized peripheral blood 
of healthy volunteers by using a gradient centrifugation of Fycoll- 
Hypaque 1171 (Pharmacia Fine Chemicals, Piscataway, NJ, USA). 
The mononuclear cells that accumulated at the interface between the 
separating medium and the plasma were removed, washed three times 
and resuspended in RPM1 1640 (Gibco) medium. The mononuclear 
cell suspension contained 80-85% lymphocytes and 1%20% 
monocytes. These cells were diluted to a concentration of 2.5 X 10’ 
cells/ml in RPMI 1640 medium containing heat-inactivated (30 min 
at 56OC), 10% FCS, as well as HEPES (25 mM), penicillin G 
(200 U/ml), gentamicin (IO fig/ml), L-glutamine (0.3 mg/mI), this 
will be referred to as complete medium (CRPMI). The cells were in- 
cubated for 72 h at 37°C in a 5% COz-humidified atmosphere in 
multiwell plates (Falcon, Italy), with or without Con A lOpg/ml 
(Sigma, St. Louis, MO, USA). After 66 h, 2&i of (‘Hlthymidine 
was added to each well and the incubation was continued for 6 h at 
37°C. 
The uptake of [3H]thymidine was quantified by trapping and 
washing the lymphocytes on glass filter in a Skatron cell harvester 
(Flow Laboratories, Milano, Italy) and counting the radioactivity on 
glass fiber filters (Flow Lab.). The results were expressed as the mean 
counts per min (cpm) + SD, and the percentage of inhibition of T lym- 
phocyte uptakeof [3H]thymidine by hrll-lra was calculated from the 
net uptake of radioactivity of stimulated T lymphocytes in the 
presence of hrIL-lra, at different concentrations, to that of the 
absence of hrll-lra. Antiserum anti-IL-10 was added at different 
concentrations 30 min before adding the mitogen Con A (Sigma) or 
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I+& I 
e=hrlL.lrn 2,Sng/1+Cocr.A IOJ@II~I 
I-hrlL.lm O,2Sng/lltl+Coll.h 10~&/11l1 
g41rll.lra O,O2sng/rl~l*coll.A l0~@tll 
h-hrlL* t m 0,002Sn~1/(nl*Can~h IO@~/lnl 
PI& I. The hiatoprm represents the c.p<m, of >H-TdR incorporation 
by lymphocytes stimulated with Con A (IO~g/ml) for 72 h rnd 
pretreated wilh aerial concentrations of IL.lre for 2 h. The deta are 
reprenentnk! of 4 experiments and the values reprerent the mean e 
SD of trlpllcete determlaatimn. 
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[mefhyl-‘H]Thymidine (3H-TdR) (specific activity 29 CVmmol), was 
purchased from New England Nuclear, Boston, MA, USA. hrIL-lra 
(Upjohn Co., Kalamazoo, Ml) was a kind gift from Dr Daniel 
Tracey. hrlL-2 was purchased from Cetus Co. (Emeryville, CA, 
USA). 
2.2. ELBA for IL-la 
PBMC (2.5 x lO”/ml) were cultured for 24 h with and without 
Con A. The levels of IL-lru in PBMC culture supernatants were deter- 
mined by a cytokine-specific ELISA obtained from ENDOGEN Inc. 
(Boston, MA). The kit is composed of 96 determinations and the 
assays were performed exactly as recommended by the manufacturer. 
The ELISA reader was set at 405 nm absorbance and all the 
samples were read after 1 h incubation at room temperature. The 
standard curve was constructed by plotting the mean absorbance of 
the interleukin standard dilutions against the concentration of the in- 
terleukin standards. By interpolation from the absorbance values (Y 
axis), the interleukin values (Xaxis) were determined by comparison 
to the standard curves. All samples were assayed in triplicate. Results 
are expressed as pg/ml (it SD). 
LPS was purchased from Sigma and was used at a concentration of 
IO ng/ml. 
3. RESULTS 
Peripheral blood mononuclear cell mitogen stimula- 
tion is a good model to study the induction of DNA syn- 
thesis and its inhibition by many antagonists. In addi- 
tion, it has been suggested that IL-1 influences and 
potentiates the function of certain T lymphocyte pro- 
liferation [l&19,25]. In Fig. 1 we show the inhibition of 
DNA synthesis which occurs in PBMC when pretreated 
Table I 
Treatment ‘H-TdR c.p.m. -C SD P=z 
Control 
Con A 2,ug 
Con A 10,~~ 
Con A SOpg 
(I) hrll-lra 250 ng,/ml + Con A 
IO ,&ml (hrlL-lra and Con A 
1099 f 96 
21834 f 2006 
50226 f 2561 




are incubated at the same time) 44 177 k 2038 0.05 
(2) hrll-lra 250 ng/ml + Con A 
IO &ml (hrlL”lra is incubated 
30 min before Con A) 35452 k I601 0.005 
(3) hrlL-lra 250 ng/ml + Con A 
IOpg/ml (IrrlL-lra is incubated 
2 h before Con A) 25979 f 203 I 0.001 
(4) hrll.-lra 250 q/ml + Con A 
IO fig/ml (hrlL-Ire is incubated 
overnight before Con A) 2G637 f 1346 0.001 
(5) Con A IO~cg/ml + hrll-lrn 
250 ng/mt (hrlL-lra is incubated 
2 h after Con A) 47459 * 2189 N.S. 
(6) Con A IOpg/ml + hrlL-lra 
250 trg/ml (hrlt-lra is incubated 
66 h after Con A) Sl8OS L 4YO1 N.S. 
This time-course tirblc rcpresentr the c.p,m, of ‘H.TdK incorporation 
by lymphocytes stimulated with Con A ror 72 h and lreatcd with 
IL-lro (2SO ng/ml) at different times before and after Con A, The 
PfMC were treated with different conccnlrati~n% of Con A. The data 
arc reprcnentative of 4 cxpcrimcnln nnd the vrluer rcpre*ent the nmn 
+ Sf3 of IripliCttle delerttiilialiol~~, B vnlue% (Sludcnt’r m%l) Ire 
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f=hrIL- I B 501Jg/ml 
g=hrlL-lfl 400ng/ml+ Con A 10pg/ml 
h=hrIL-IB 200ng/ml+ Con A 10tag/ml 
i=hrlL-IB 100ng/ml+ Con A 101ag/ml 
j=hrlL-1B 50ng/ml + Con A 101ag/ml 
kfhrlL-lra 250ng/ml * Con A 10pg/ml 
lfhrlL-lra 250ng/ml hrlL-IB 400ng/ml+Con A 
m=hrIL- Ira 250ng/ml +hrIL-lfl 200ng/ml+ConA 
n=hrIL-lra 250ng/ml+hrIL-lfl 100ng/ml+ ConA 
o=hrIL-lra 250ng/ml +hrIL-IB 50ng/ml + ConA 
Fig. 2. This graph represents he c.p.m, o f  ~H-TdR incorporation by lymphoeytes stimulated (bars: b, g, h, i, j, k, I, m, n, o) and non-stimulated 
(bars: a, c, d, e, f) with Con A for 72 h. Bars c, d, e, f (no Con A) and bars l, m, n, o (with Con A) were pretreated for 2 h with IL-lra. Bars 
g, h, i, j and 1, m, n, o were treated simultaneously with hrlL-l,6' (different cone.) + Con A. Bar 'a' is untreated cells. Bar 'b'  is treated only with 
Con A and bar 'k'  is pretreated for 2 h with IL. l ra and then added Con A. The data are representative of 4 experiments and the values represent 
the mean --, $D of  triplicate determinations. 
for 2 11 with hrlL-lra and then treated with the mitogen 
Con A (10/zg/ml). This effect is dose-dependent with a 
maximum inhibition at hrIL-lra (250 ng/ml) and 
minimum at hrIL-lra (2.5 pg/ml). Repeated trials have 
demonstrated that hrIL-I ra inhibits lymphocyte activa- 
tion and proliferation. The time-course action of 
hrIL-lra is shown in Table I. The first part of this table 
shows the optimal mitogenic effect of Con A by using 
3 different concentrations (2, 10 and 50 ag/ml). In the 
second part of Table I we show that when the PBMC 
are preineubated for 2 h. or overnight with hrIL-lra 
(250 ng/ml) there is a strong and significant inhibitory 
effect of DNA synthesis. A little less inhibition was ob- 
tained with 30 rain pretreatment. While, when cells are 
treated 2 h after Con A, or 6 h before the end of 
culture, together with 3H-TdR, to exclude the possible 
interference of hrIL-lra on thymidine incorporation, 
there was no inhibition of mitogenesis. 
In another set of experiments, the PBMC cultures 
were exposed to Con A (I0 ,ug/ml), hrlL-1,6' at different 
concentration s (400,200, 100 and 50 ng/ml); hrIL. 1~ + 
Con A; hrlL-lra + Con A and hrIL-lra + hrlL-l,d'at 
different concentrations + Con A (Fig. 2). In this 
figure, we show that Con A stimulates lymphocyte 
DNA synthesis, hrlL-l~' (at different concentrations) i  
inactive, while the addition of hrlL-l~' plus Con A to 
the cells increases the lymphocyte blastogenesis, which 
is maximum at hrlL-l,6' 100 ng/ml, while 400 and 
50 ng/ml resulted to be non-significant. The cell 
pretreatments (2 11) with hrIL-1 ra (250 ng/ml), strongly 
inhibits the enhancing effect of hrlL-1,6' with Con A. 
Fig. 3 shows the lymphocyte population without 
macrophages (discarded after adherence). In these ex- 
periments the lymphocyte (PBMC) response to Con A 
was very weak owing to the absence of M~s, and the ad- 
dition of hrlL-lra to Con A did not influence these 
results; while, when the cells were treated with hrIL-1 
and Con A the 3H-TdR incorporation strongly in. 
creased. This last effect was inhibited by the pretreat- 
ment of cells for 2 h with hrIL-lra (250 ng/ml). 
In Table II we show the dose-response inhibitory ef- 
fect of hrIL-lra on PBMC 2 h preincubations, and then 
adding Con A (10,ag/ml). When the PBMCs were 
treated with hrlL-2 plus Con A the mitogenesis in- 
creased, the effect being strongly inhibited by hrIL-lra 
(250 ng/ml), In other experiments we pretreated PBMC 
(2.5 × l0 ~) ['or 2 h with hrIL-lra (250 ng/ml) and then 
added LPS (10 ng/ml) cultured for 24 h (Table Ill). In 
139 












k-contrul I-Control * uIL+lra 25Ondml (no Con A) 
B-Con A IOygfml 2-hrIL.lm 2SOngIml + Can A IOp~ml 
C-hrlLI0 4OGn#ml* Con A lOg+nl I-hrIL.lm ZSOnO/ml + hrlL-IO 400nglml + Con A IO@ml 
D-hrlLIQ ZOOn~ml l Can A IOpdml 4.hrll-lra ZSOnglml + hlL.lO 2OOnglml + Con A lO@nl 
E-hrlL.ID lOOng/ml + Con A IOpdml S- hrlL-lm 2SOnglml+ hrlL.lO lOOng/ml l Con A IOfidml 
F-hrlL.10 SOdml + Con A IO&ml 6- hrlL.lra 2SOnglml + hrlL-I8 SOng/ml + Con A lO~e/ml 
Fig. 3. The graph represents the c.p.m. of ‘H-TdR incorporation by 
a lymphocyte population without macrophages, discarded by 
adherence, stimulated with Con A for 72 h. The cells are pretreated 
with IL-lra (columns: 3-6) and columns C-F are not pretreated with 
hrll-lra. To both groups were added hrlL-I@ plus Con A. Co!umn 
A = untreated cells; column I = pretreated with only hrll-lra; 
column B = treated only with Con A: and column 2 = pretreated with 
hrll-lra then with Con A (after 2 h). The data are representative of 
4 experiments and the values represent the mean f SD of triplicate 
determinations. 
these experiments hrIL-lra comuletelv abolished LPS- . . 
induced IL-la generation. 
Each figure and table presented in this paper are 
representative of 4 experiments using 4 different 
healthy donors. 
4. DISCUSSION 
Recently it has been reported that the role of antigen- 
activated macrophages in monokine production and T- 
cell activation is critical to the host’s orchestration of 
the immune response [S]. Moreover, it is well known 
that antigens timulate macrophages to generate IL-l, 
which is an important early signal for the activation of 
resting T-ceils to becomr: antigen-specific T-cells, 
capable of expressing the IL-2 receptor, producing solu- 
ble IL-2 and secreting other lymphokines uch as IL-4, 
IL-6, interferon-y (IFN-y), etc. [20]. The exact 
mechanism of IL-1 production and regulation by 
macrophages i still somewhat of an enigma. However, 
the latest results reported in the immunological 
literature make it clear that hrIL-lra, a cytokine also 
released by MBS, down-regulate IL-1 production by 
human monocytes, 
In our study, we show that lymphocyte blastogenesis, 
induced by the mitogen Con A is inhibited by hrIL-lra 
in a dose-dependent manner, This effect is most pro- 
bably due to the inhibitory effect of hrIL-lra on 
macrophage IL-I production, necessary for T-cell ac- 
tivation. Qur results are in accordance with Arend et 
Table II 
Treatment ‘H-TdR incorporation PC 
(c.p.m.)k SD 
Nil 
hrll-lra (no Con A) 
hrlL-2 (no Con A) 
Con A (IO&ml) 
hrll-lra (250 ng/ml) + Con A 
(lO$g/ml) 
hrll-lra (25 ng/ml) + Con A 
(10 #g/ml) 
hrll-lra (2.5 ng/ml) I- Con A 
(IOrg/ml) 
hrll-lra (0.25 ng/ml) + Con A 
(lOflg/ml) 
hrll-lra (0.025 ng/ml) + Con A 
(IO&ml) 
hrll-lra (0.0025 ng/ml) + Con A 
( 10 fig/ml) 
hrlL-2 (1000 U/ml) + Con A 
(IO fig/ml) 
hrll-lra (250 ng/ml) + hrlL-2 
(I000 U/ml) + Con A (lOpg/ml) 
1150 -e 380 
1063 2 401 
9560 k 2019 
54280 zk 1560 
26150 k 1320 
29820 -t Ill2 
32988 rt 1091 
38147 -t 1667 
46321 Jr 2153 
52686 zk 2667 
90750 + 3410 











[3H]Thymidine incorporation and mean + SD in human PBMC after 
exposure to Con A (IO&ml), hrll-lra at different concentrations 
(2 h before Con A or hrlL-2), alone or in combination, and hrlL-2 
alone and in combination with Con A and with hrll-lra + Con A, 
during 72 h incubation time. P values (Student’s I-test) are calculated 
by comparing hrIL-lra + Con A, hrlL-2 + Con A or hrll-It-a + 
hrlL-2 + Con A-treated cells with Con A (Y) alone 
al., who found that hrIL-lra exhibits a dose-responsive 
inhibition of IL-la and IL-l,& augmentation of PHA- 
induced murine lymphocyte proliferation [121. In addi- 
tion, these authors found that hrIL-lra is a strong in- 
hibitor of PGE2. Since there is evidence that pro- 
staglandins, in physiological concentrations, are im- 
plicated in many cellular control processes and may 
play an important role in lymphocyte stimulation in 
vitro (being that PGs stimulate adenylcyclase activity 
and markedly increase the CAMP levels) [21,22], it is 
also possible that the down-regulation of PGE2 by 
hrIL-lra may contribute to the inhibition of lym- 
phocyte blastogenesis. 
In this study, the suppression by hrIL-lra pretreated 
peripheral blood mononuclear cells on mitogen- 
stimulated proliferation was maximum at 250 ng/mI, 
the highest concentration tested. However, we did not 
test higher concentrations of IL-Ira on the basis of 
Table 111 
Treatment IL-In (pg/ml) I SD 
Conlrol 109 zk 96 
l”PS (IO ng/ml) 4546 k 801 
hrlt-lra (250 ng/mI) 115 * 86 
ItrlL-lra (2S0 ng/ml) + LPS (IO ng/ml) 175 + 98 
Human PBMC (2,5 x IO” cells/ml) in 3 healthy donors (tncnn or 3 
cxpcritnents) pretreated or not with ML-lro (2 II) and then wiva~cd 
with LPS (IO ng/ml) far 24 It nt 37X, 5% CO3 (EL&A). 
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inhibitory effect of hrIL-lra on mitogenesis is max- 
imum when the PBMC were preincubated with this 
monocyte product for 2 h. When monocytes were 
discarded from the entire population of PBMC and on- 
ly the lymphocytes were cultured, the treatment with 
Con A was effective only when exogenous hrIL-1 was 
added at different concentrations. This effect was par- 
tially inhibited by 2 h pretreatment of hrIL-lra, sug- 
gesting that hrIL-lra down-regulated not only en- 
dogenous IL-l released by macrophages but also an- 
tagonizes the exogenous hrIL-I. 
This work was supported by the Italian Ministry of ‘Ricerca Scien- 
tifica e Tecnologica (40%, 1990)‘. 
The restorative effects exerted by hrIL-2 after the in- 
hibition of hrIL-lra demonstrate that the block of IL-1 
by hrIL-Ira consequently leads to the lack of produc- 
tion of IL-2, an important growth factor for T-cells. 
Moreover, the reversibility of hrIL-lra’s action on the 
cells indicate a non-toxic effect, probably involving the 
down-regulation of the gene expression through the in- 
hibition of mRNA of IL-l. Since the activation of T 
cells involves IL-I as the first signal in the production of 
other cytokines, such as the growth factor IL-2 the in- 
hibition of mitogen stimulated lymphocyte DNA syn- 
thesis by hrIL-lra is most probably due to the inhibition 
of interleukin-1 as is shown in Table III. However the 
activation of T cells has not been fully elucidated. There 
are different points of view regarding IL-l’s ability to 
stimulate T cells. The prominent belief is that IL-l is a 
factor that promotes mitogen-driven T cell 
blastogenesis [161. Pereira, Miller and Shevach reported 
two alternative pathways for T cell activation: one 
pathway is cyclosporin-resistant and IL-2 independent; 
the second is cyclosporin-sensitive, cytokine dependent 
(including IL-2), postulating the existence of a new T 
cell growth factor released by T lymphocytes [26]. 
Recently, Mizel reported that CD4 T cells may be clivid- 
ed into two subpopulations, THl and TH2, which are 
both activated by mitogen presenting cells and produce 
different interleukins: TH 1 release IL-2, IL-3 and IFNy 
which activates macrophages, while TH2 respond to the 
presented antigen and IL-1 to release IL-3, IL-4 and 
IL-6 1271. 
The existence of IL-1 inhibitor (IL-li) was previously 
described by Dinarello et al. in 1982 which 
demonstrated the existence of a circulating thymocyte 
suppressor factor during cndotoxic fever in humans. 
IL-li biocks the binding of IL-1 to its receptors on T- 
cells but does not block the binding of TNFcv or IL-2 
[23,24]. It is possible chat IL-lra and IL-li are the same 
factor, In fact, these two compounds both had a potent 
effect on T cell activation and proliferation as con- 
firmed by our studies. 
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